|

Relugolix Clinical Trials

11 actively recruiting trials across 9 locations

Also known as: N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, TAK385, medroxyprogesterone acetate, megestrol acetate

Phoenix, Arizona2 trials

Other1 trial

Birmingham, Alabama1 trial

Anchorage, Alaska1 trial

Scottsdale, Arizona1 trial

Orlando, Florida1 trial

Atlanta, Georgia1 trial

Chicago, Illinois1 trial

Boston, Massachusetts1 trial

Columbus, Ohio1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.